STOCK TITAN

IceCure Medical Ltd. (ICCM) Stock News

ICCM NASDAQ

IceCure Medical Ltd. develops and markets liquid-nitrogen-based cryoablation systems for minimally invasive tumor destruction. Its flagship ProSense® system is used for benign and cancerous lesions, with company updates centered on breast, kidney, bone and lung cancer indications and on markets where the device is cleared or approved, including the United States, Europe and Asia.

News about ICCM commonly covers ProSense commercialization, FDA-related breast cancer developments, post-market study activity, clinical evidence such as the ICESECRET kidney cancer study, medical-conference presentations, financial and operating results, and governance changes. The company’s updates also address physician training, reimbursement context and shareholder matters tied to its ordinary shares.

Rhea-AI Summary

IceCure Medical (NASDAQ: ICCM) will release its financial and operating results before the market opens on November 18, 2026.

The results will cover the nine months ended September 30, 2026. The company will discuss the results and other corporate developments on a conference call at 10:00 a.m. EST that same day. A live webcast and a recording will be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
earnings date
-
Rhea-AI Summary

IceCure Medical (ICCM) has received a Chinese patent covering a connector used in its cryogenic technology platform for freezing tumors. The grant from the China National Intellectual Property Administration adds to a portfolio containing 42 patents across the United States, Europe, Great Britain, China and Japan.

The patent follows September 2026 approval from China's National Medical Products Administration to market ProSense and its associated cryoprobes in China. IceCure's patent portfolio covers its technology platform and innovations intended for current and future products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.82%
Tags
none
-
Rhea-AI Summary

IceCure Medical (ICCM) completed the first patient treatment in its ChoICE post-marketing study evaluating ProSense cryoablation for low-risk breast cancer.

The patient was enrolled and treated at West Cancer Center & Research Institute in Germantown, Tennessee, by Dr. Richard E. Fine. Cryoablation destroys tumors by freezing. The study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites and generate real-world data within ProSense's FDA-cleared indication. IceCure expects participating sites to operate as both study centers and commercial sites, offering treatment to eligible patients outside the study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
Rhea-AI Summary

IceCure Medical (ICCM) enrolled the first two patients at U.S. sites in its ChoICE post-marketing study of ProSense breast cancer cryoablation. The study evaluates local treatment of low-risk breast cancer using freezing to destroy tumors. The patients were enrolled at West Cancer Center & Research Institute in Germantown, Tennessee, and Adventist Health Glendale in California.

ChoICE is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites, generating real-world data within ProSense's FDA-cleared indication. Both initial sites received institutional review board approval and signed site agreements before becoming eligible to enroll patients in August 2026. Legacy Health's Good Samaritan Medical Center in Portland, Oregon, joined the network earlier this month. IceCure expects participating centers to also operate as commercial sites, treating eligible patients outside the study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
-
Rhea-AI Summary

IceCure Medical (Nasdaq: ICCM) presented ProSense breast cancer cryoablation clinical data at the European Society of Breast Imaging’s 2026 annual meeting.

Presentations reported 12-month objective response rates, a measure of tumor response, of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone. Cryoablation destroys tumors by freezing. The meeting took place in Maastricht, the Netherlands.

ProSense featured in two scientific sessions, including findings on elderly breast cancer patients ineligible for surgery. IceCure hosted two clinical workshops, each attracting nearly 70 participants. Two posters by ProSense users addressed one-year outcomes for breast lesions in Romania and imaging to predict tissue response after breast cryoablation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
-
Rhea-AI Summary

IceCure Medical (ICCM) added Legacy Health in Portland, Oregon, as a U.S. clinical site for its ProSense ChoICE breast cancer study. Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center will participate in the post-marketing study evaluating local treatment of low-risk breast cancer. Cryoablation destroys tumors by freezing them.

The FDA-approved post-market study is designed to evaluate ProSense safety and effectiveness as an alternative to surgery for eligible patients. IceCure expects enrollment of approximately 400 patients across up to 30 U.S. clinical sites. A standardized protocol will generate additional real-world clinical data. Co-primary investigator Nathalie Johnson will lead the Legacy site's participation, with Marco Aru and Jennifer Garreau as co-investigators.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.53%
Tags
none
Rhea-AI Summary

IceCure Medical (ICCM) received Class III medical device approval from China’s National Medical Products Administration (NMPA) for its ProSense® cryoablation system and associated cryoprobes. This approval allows ProSense® to be marketed in China in line with the granted registration.

The company describes the NMPA decision as an important regulatory milestone that strengthens its global regulatory position and expands the markets where ProSense® may be commercialized. ProSense®, IceCure’s flagship liquid-nitrogen-based cryoablation system, is designed as a minimally invasive option to surgical tumor removal and is already marketed for cleared and approved indications in the U.S., Europe, and Asia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary

IceCure Medical (Nasdaq: ICCM) signed an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands, covering breast cancer and interventional oncology. Scovas will initially act as exclusive distributor, with a view to negotiating a longer-term agreement subject to both parties.

According to IceCure, the deal supports market development and clinical education in a country with strong interventional radiology expertise. The Netherlands-hosted, independent multicenter randomized THERMAC trial has advanced to Phase III focusing on cryoablation, after earlier data showed ProSense® achieved the highest complete ablation rate among evaluated thermal ablation techniques, with a 94% success rate, 0% complication rate and 100% treatment tolerance without general anesthesia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.58%
Tags
none
-
Rhea-AI Summary

IceCure Medical (NASDAQ: ICCM) reported that the Institutional Review Board of West Cancer Center & Research Institute in Germantown, Tennessee has approved the Company’s post-marketing ChoICE Study evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer, enabling patient enrollment in the coming weeks.

ProSense® is the first and only device with U.S. FDA marketing authorization for local treatment of low-risk breast cancer with endocrine therapy in women aged 70 and above. Prior ICE3 trial results showed a 3.1% local recurrence rate and very high cosmetic satisfaction among patients and physicians, which supported this authorization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
Rhea-AI Summary

IceCure Medical (NASDAQ: ICCM) highlighted two new peer-reviewed U.S. publications supporting the role of its ProSense® cryoablation system in breast cancer treatment de-escalation. One review in Clinical Breast Cancer discusses clinical evidence, procedural aspects and ProSense®'s FDA marketing authorization, its inclusion in updated American Society of Breast Surgeons guidelines, and five-year ICE3 trial outcomes showing a 3.1% IBTR rate in selected patients.

A second article in the Journal of Breast Imaging addresses cryoablation of axillary lymph node metastases for breast cancer patients who are poor surgical candidates or decline surgery, reporting high technical success and low complication rates in both curative and palliative settings, and broadening discussion beyond primary tumors to regional nodal disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
none

FAQ

What is the current stock price of IceCure Medical (ICCM)?

IceCure Medical (ICCM) last closed at $0.7300.

What is the market cap of IceCure Medical (ICCM)?

The market cap of IceCure Medical (ICCM) is approximately $2.5M.